Form 4: Clene Inc. Director Shalom Jacobovitz Receives Stock Options

Director Shalom Jacobovitz was granted 4,291 stock options in Clene Inc. as part of the company's 2020 Stock Plan.

Summary

• Director Shalom Jacobovitz received two grants of stock options on May 21, 2026.
• The total grant consists of 4,291 shares of common stock with an exercise price of $6.81 per share.
• 1,500 options vest in 12 equal monthly installments starting June 21, 2026.
• 2,791 options vested immediately upon the grant date.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation that carries no significant market-moving sentiment.

Positives

• Alignment of director interests with shareholders through equity-based compensation.

Negatives

• Issuance of stock options results in potential future dilution for existing shareholders.

Risks

• The value of the options is dependent on the future market performance of Clene Inc. common stock exceeding the $6.81 exercise price.

Future Outlook

The options expire on May 20, 2036, indicating a long-term incentive structure for the director.

Industry Context

StockSavvy.ai notes that director equity grants are standard corporate governance practices intended to align leadership incentives with long-term shareholder value, particularly in the biotechnology sector where Clene Inc. operates.

Comparison to Industry Standards

• The use of the Amended 2020 Stock Plan for director compensation is consistent with standard practices for small-cap biotechnology firms.
• Immediate vesting of a portion of the grant is a common practice for director compensation packages.

Stakeholder Impact

• Minor dilution impact on existing shareholders due to the issuance of new stock options.

Next Steps

• Vesting of 1,500 options in monthly installments beginning June 21, 2026.

Key Dates

Keywords

Clene Inc, CLNN, Form 4, Insider Trading, Stock Options, Director Compensation